Related Experiment Video
Updated: May 26, 2026
Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
Published on: March 15, 2022
Use of tailored loading-dose clopidogrel in patients undergoing selected percutaneous coronary intervention based on
Kang Meng1, Shu-Zheng Lü, Hua-Gang Zhu
1Department of Cardiology, the Key Laboratory of Remodeling-related Cardiovascular Diseases, Anzhen Hospital, Capital Medical University, Beijing 100029, China.
Insights
An adjusted clopidogrel loading dose significantly improved antiplatelet aggregation compared to a standard dose. This approach reduced major adverse cardiac events in percutaneous coronary intervention patients without increasing bleeding risk.
Area of Science:
- Cardiology
- Pharmacology
- Interventional Cardiology
Background:
- Adenosine phosphate-mediated platelet aggregation is a key predictor of adverse cardiac events post-percutaneous coronary intervention (PCI).
- Optimizing antiplatelet therapy is crucial for improving outcomes in PCI patients.
Purpose of the Study:
- To evaluate if an adjusted clopidogrel loading dose regimen enhances inhibition of platelet aggregation.
- To compare the efficacy of adjusted versus standard clopidogrel loading doses in patients undergoing PCI.
Main Methods:
- A multicenter, prospective, randomized study involving 205 patients undergoing selected PCI.
- Patients received either domestic clopidogrel (Talcom) or Plavix, with up to three additional 300-mg loading doses to achieve >50% reduction in adenosine diphosphate-mediated platelet aggregation.
- Primary endpoint: >50% decrease in platelet aggregation; Secondary endpoint: major adverse cardiovascular events at 12 months.
Main Results:
- The adjusted loading dose regimen achieved significantly better platelet aggregation inhibition (73%) compared to the rational dose (48%, P=0.028).
- No significant differences in efficacy were observed between Talcom and Plavix groups across different dosing strategies.
- Major adverse cardiac events and stent thrombosis rates were similar between groups at 12-month follow-up.
Conclusions:
- An adjusted clopidogrel loading dose strategy effectively enhances antiplatelet aggregation.
- This optimized dosing may reduce 1-year major adverse cardiac events in PCI patients without increasing bleeding risk.
Background:
Adenosine phosphate-mediated platelet aggregation is a prognostic factor for major adverse cardiac events in patients who have undergone selective percutaneous coronary interventions. This study aimed to assess whether an adjusted loading dose of clopidogrel could more effectively inhibit platelet aggregation in patients undergoing selected percutaneous coronary intervention.
Methods:
A total of 205 patients undergoing selected percutaneous coronary intervention were enrolled in this multicenter, prospective, randomized study. Patients receiving domestic clopidogrel (n = 104) served as the Talcom (Taijia) group; others (n = 101) received Plavix, the Plavix group. Patients received up to 3 additional 300-mg loading doses of clopidogrel to decrease the adenosine phosphate-mediated platelet aggregation index by more than 50% (the primary endpoint) compared with the baseline. The secondary endpoint was major adverse cardiovascular events at 12 months.
Results:
Compared with the rational loading dosage, the tailored loading dosage better inhibited platelet aggregation based on a > 50% decrease in adenosine phosphate-mediated platelet aggregation (rational loading dosage vs. tailored loading dosage, 48% vs. 73%, P = 0.028). There was no significant difference in the eligible index between the Talcom and Plavix groups (47% vs. 49% at 300 mg; 62% vs. 59% at 600 mg; 74% vs. 72% at 900 mg; P > 0.05) based on a standard adenosine diphosphate-mediated platelet aggregation decrease of > 50%. After 12 months of follow-up, there were no significant differences in major adverse cardiac events (2.5% vs. 2.9%, P = 5.43). No acute or subacute stent thrombosis events occurred.
Conclusion:
An adjusted loading dose of clopidogrel could have significant effects on antiplatelet aggregation compared with a rational dose, decreasing 1-year major adverse cardiac events in patients undergoing percutaneous coronary interventions based on adenosine phosphate-mediated platelet aggregation with no increase in bleeding.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:27Peripheral Artery Disease III: Interprofessional Care
01:27Coronary Artery Disease V: Interprofessional Care
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:26Angina IV: Management
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...